Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTI-Hematopoietic
- Development stage
- Preclinical
- Lead developer
- Rejuvenation Technologies
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
RTI-Hematopoietic is a preclinical mRNA-based therapeutic being developed by Rejuvenation Technologies for the treatment of bone marrow failure and cytopenia. The therapy utilizes modified mRNA encoding telomerase reverse transcriptase (TERT) encapsulated within proprietary lipid nanoparticles (LNPs). By delivering TERT mRNA to hematopoietic stem cells, the drug aims to transiently activate the telomerase enzyme, thereby extending telomeres and restoring the regenerative capacity of the bone marrow. This approach is intended to treat conditions characterized by telomere shortening, such as dyskeratosis congenita and other forms of aplastic anemia, by reversing cellular senescence in the hematopoietic compartment.
- Other names
- TeloHSCmRNA Telomerase Activator (hematopoietic)
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on RTI-Hematopoietic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTI-Hematopoietic.